Efficacy and safety of pre-emptive tapentadol on pain control in total knee arthroplasty: A randomized, double-blind, placebo-controlled trial

doi:10.5312/wjo.v16.i10.110233

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

(37)

(68)

(0)

(9)

(928)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Orthopedics

ISSN

2218-5836

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Orthop. Oct 18, 2025; 16(10): 110233
Published online Oct 18, 2025. doi: 10.5312/wjo.v16.i10.110233

Full Size Figure Download Figure

Figure 3 Receiver operating characteristic of plasma cholecystokinin concentration and tapentadol concentration with pain intensity in visual analog scale. ROC: Receiver operating characteristic; VAS: Visual analog scale.

Citation: Bhattacharjee S, Srinivasan A, Tripathy SK, Doki SK, Hota D. Efficacy and safety of pre-emptive tapentadol on pain control in total knee arthroplasty: A randomized, double-blind, placebo-controlled trial. World J Orthop 2025; 16(10): 110233
URL: https://www.wjgnet.com/2218-5836/full/v16/i10/110233.htm
DOI: https://dx.doi.org/10.5312/wjo.v16.i10.110233

Bhattacharjee S, Srinivasan A, Tripathy SK, Doki SK, Hota D. Efficacy and safety of pre-emptive tapentadol on pain control in total knee arthroplasty: A randomized, double-blind, placebo-controlled trial. World J Orthop 2025; 16(10): 110233 [PMID: 41181035 DOI: 10.5312/wjo.v16.i10.110233]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.